Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5877451 | Cor et Vasa | 2014 | 8 Pages |
Abstract
Twelve months dual antiplatelet therapy (DAPT) based on a combination of acetylsalicylic acid and purine receptor P2Y12 inhibitor is a standard for all patients with acute coronary syndrome (unstable angina pectoris, NSTEMI and STEMI). Previous sub-analysis of CURE and ACUITY studies suggested that DAPT could bring benefit even for patients treated by surgical revascularization. Sub-analysis of PLATO trial conducted on 1261 patients, who underwent surgical revascularization within 12 months, demonstrated a reduction of cardiovascular and total mortality within a group of patients treated by ticagrelor and acetylsalicylic acid compared to patients treated by clopidogrel and acetylsalicylic acid.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
JiÅÃ PaÅenica, Petr NÄmec,